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Abstract
Background:  Survivin, an inhibitor of apoptosis is expressed in several human cancers. Its
expression is known to be associated with poor clinical outcome, but not widely studied in
pancreatic cancer. We performed this study to determine the survivin expression in pancreatic
cancer and its clinical significance as a prognostic factor.
Methods: We performed immunohistochemical staining for survivin, p53, and Bax in formalin-
fixed, paraffin-embedded block from forty-nine pancreatic tissues. To determine the association
with clinical course, we reviewed the patients' clinical record.
Results:  Of the 49 cases of pancreatic cancer, 46 cases (93.9%) were positive for survivin
expression. There was no significant association between survivin expression and p53 or bax. For
clinicopathological parameters, perineural invasion was more common in survivin positive and
venous invasion was more common in survivin negative (p = 0.041 and 0.040, respectively).
Responsiveness to chemotherapy appeared to be slightly better in patients with low survivin
expression.
Conclusion: Survivin expression may be associated with venous or perineural invasion, indicating
metastatic route, and seems to have a potential as a predictive marker for chemotherapy. Further
study of large scale is required to determine the clinical significance of survivin expression in
pancreatic cancer.
Background
Survivin has recently been identified as a novel inhibitor
of apoptosis (IAP). It blocks common downstream ele-
ments of both the mitochondrial pathway and the death
receptor pathway, by directly inhibiting terminal effector
caspase-3, caspase-7, and caspase-9 activity[1,2]. Thus, it
inhibits apoptosis pathway differently from bcl-2, which
blocks mitochondrial cytochrome c release into the
cytosol, resulting in the inhibition of mitochondrial
apoptotic pathway. Survivin is expressed during
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embryonic and fetal development but is undetectable in
terminally differentiated normal adult tissue. However, it
is re-expressed in transformed cell lines and several
human cancer cells at a frequency of 34–100 % [3,4]. As a
prognostic factor, survivin expression is significantly asso-
ciated with poor clinical outcome in cancers, such as neu-
roblastoma, colorectal cancer, breast cancer, lung cancer
and esophageal cancer [5-10].
Survivin expression in pancreatic cancer has not been
widely studied. Satoh et al reported that survivin was
expressed in malignant portion of intraductal papillary-
mucinous tumor (IPMT) but not in chronic pancreatitis,
and thus proposed that survivin expression may be upreg-
ulated at an early stage of tumorigenesis by reducing can-
cer cell apoptosis [11]. In another study, Asanuma et al
reported that survivin acts as an inducible radioresistance
factor in pancreatic cancer cell line [12].
In the present study, we investigated survivin expression
in pancreatic cancer and its association with clinical
outcome.
Methods
Patients and specimens
Formalin-fixed, paraffin-embedded blocks from forty-
nine surgically resected pancreatic tumor tissues were
studied. All samples were collected under protocols
approved by the local Institutional Review Board (IRB).
All patients were diagnosed with pancreatic cancer at
Kangnam St. Mary's hospital between May 1994 and
November 2001. Patients' clinicopathological characteris-
tics are summarized in Table 1 &2. Median age was 59
years (range, 33–76 years). According to AJCC cancer
stage system (4th ed, 2002), 34 patients (69.4%) had stage
I and II disease, and 10 patients (20.4%) had stage III. dis-
ease. Fourteen patients had only palliative resection and
treated combination chemotherapy with epirubicin, cispl-
atin and 5-FU. Of 35 patients who had curative surgery, 20
patients (40.8%) underwent adjuvant treatment with
radiotherapy. Recurrent cancer developed in 18 patients,
and the median time to recurrence was 156 days (range,
58–1499 days).
Tissue microarray
To construct the tissue microarray block, small core biop-
sies were taken from non-necrotic, morphologically repre-
sentative areas of paraffin-embedded tumor tissues and
assembled on a recipient paraffin block. This was per-
formed using a precision instrument (Micro Digital Co.
Korea). The biopsied core was 3.0 mm in diameter, which
was sufficient for assessing the morphological features in
the tissues, and then 30 cores were assembled on a recipi-
ent paraffin block. After construction, 5 µm sections were
cut and hematoxylin-eosin staining was performed on the
initial slide to verify the histology.
Immunohistochemistry
Immunohistochemical staining was performed on 5 µm
sections of the tissue microarray blocks. Paraffin sections
were mounted on superfrost glass slides, deparaffinized
Table 1: Patients' characteristics
No. of case
Age* 59 (33–76)
M:F 36:13
Chief Complaint Pain 20(40.8%)
Jaundice 18(36.7%)
Indigestion 6(12.2%)
Others 5(10.1%)
Location Head 35(71.4%)
Body 1(2.0%)
Tail 7(14.3%)
Body & Tail 6(12.3%)
Stage I 8(16.3%)
II 26(53.1%)
III 10(20.4%)
IV 5(10.2%)
Adjuvant treatment Yes 20(40.8%)
No 14(28.6%)
Recurrence after curative surgery 18/35+
*: median,
+: number of recurrence/total number of operable cases
Table 2: Pathological characteristics
number
differentiation well 8 (16.3%)
moderate 34 (69.4%)
poorly 3 (6.1%)
others 4(8.2%)
lymphatic invasion + 28 (57.1%)
-1 8  ( 3 6 . 7 % )
vein invasion + 10 (20.4%)
-3 6  ( 7 3 . 5 % )
perineural invasion + 34 (69.4%)
-1 2  ( 2 4 . 5 % )BMC Cancer 2005, 5:127 http://www.biomedcentral.com/1471-2407/5/127
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and rehydrated in a graded ethanol series, and then sub-
jected to microwave antigen retrieval. Endogenous perox-
idase activity was blocked using 0.3% hydrogen peroxide.
Sections were incubated for l hour at room temperature or
at 4°C overnight with the following primary antibodies at
the dilutions specified: survivin Ab-6(NeoMarkers, CA,
USA) diluted 1:50, p53 (DAKO Corporation, Carpinteria,
CA, USA) diluted 1:100, Bax (DAKO) diluted 1:200.
Immunohistochemical staining was performed using the
rabbit or mouse DAKO ChemMateTM EnVisionTM sys-
tem, and the Peroxidase/DAB Kit (DAKO). Sections were
then counterstained with Mayer hematoxylin and then
dehydrated, cleared and mounted.
Results were interpreted by two independent pathologists
who were blinded to the specific diagnosis and prognosis
for each case. Tumor cells that showed distinct nuclear or
cytoplasmic staining were considered positive. Immuno-
histochemical staining was scored on a three-tiered scale:
score 0 = less than 10% of cells positive; 1 = 10 – 49% pos-
itive; score 2 = ≥50% positive.
Statistical analysis
The SPSS (version 11.0) statistical package was used to
analyze the data. Using the Chi-square Test and the
Fisher's exact test, the immunohistochemical profiles
were compared with clinico-pathologic parameters.
Results
Expression of survivin, p53, and Bax
Of forty-nine cases of pancreatic cancer, 46 cases (93.9%)
were positive for survivin expression (Fig. 1). In immuno-
histochemical staining for p53 and Bax, sixteen cases
(32.7%) and thirty-eight cases (77.5%) were positive,
respectively (Fig. 2A & B). These are summarized in Table
3. Survivin expression was not associated with p53 or Bax
expression (p = 0.9969 and 0.0931, respectively, Table 4)
Survivin, p53, and bax expression and clinico-pathologic 
characteristics
Of 49 tissue specimens, only tumor tissues were obtained
from 3 patients due to far advanced stage. We evaluated
pathological characteristics in 46 patients. There was no
correlation between disease stage and expression of sur-
vivin, p53, or bax protein (Table 5), and no correlation
was found between survivin expression and p53 or bax
protein expression. However, perineural invasion was
more common in the survivin-positive, and venous
Immunohistochemical staining for surviving Figure 1
Immunohistochemical staining for surviving. Strong 
cytoplasmic expression for survivin in pancreatic cancer 
gland (A: × 100, B: × 400).
Immunohistochemical staining for p53 and Bax Figure 2
Immunohistochemical staining for p53 and Bax. A: 
Strong positive expression of p53 in cancer cell (× 400). B: 
Positive expression of Bax in pancreatic cancer cell(× 200).
Table 3: The result of immunohistochemical staining
Survivin p53 Bax
Score 0 3(6.1%) 33(67.3%) 11(22.4%)
Score 1 17(34.7%) 9(18.4%) 11(22.4%)
Score 2 29(59.2%) 7(14.3%) 27(55.1%)
Table 4: Survivin expression and p53, Bax in pancreatic cancer
p53 (p = 0.9969) Bax (p = 0.0931)
0 1201 2
survivin 0 2 0121 0
1 1 2 3262 9
2 1 9 6438 1 8BMC Cancer 2005, 5:127 http://www.biomedcentral.com/1471-2407/5/127
Page 4 of 6
(page number not for citation purposes)
invasion was more common in the survivin- negative
group (p = 0.041 and 0.040, respectively, Table 6).
Clinical outcome and survivin expression
We evaluated the association between survivin expression
and survival. We did not find any significant difference
correlation between survival and survivin expression (Fig
3) because only three patients showed survivin negative.
It was difficult to identify the association due to the vast
majority of patients expressing survivin.
Fourteen patients received epirubicin, cisplatin and 5-FU
combination chemotherapy as initial treatment for
advanced stage of disease. Responsiveness to chemother-
apy appeared to be slightly better in patients with low sur-
vivin expression compared to those with high expression
(28.8% vs.7.1%, respectively; Table 7), although there
was no statistically significant correlation. We also inves-
tigated the efficacy of chemotherapy and Bax expression,
but all patients who treated with chemotherapy showed
2+ in Bax expression. Therefore, we did not analyze statis-
tical significance.
Discussion
Survivin, an IAP, has been studied as a prognostic marker
in various cancers. Adida et al reported that survivin
expression in neuroblastoma correlated with unfavorable
histology, aggressive and disseminated disease [5]. In
colorectal cancer and breast cancer, patients with survivin-
positive tumors had a decreased apoptotic index and
worse survival rates than those with survivin-negative
tumors [7,8]. In addition, survivin expression correlated
with poor prognosis in esophageal cancer and non-small
cell lung cancer [9,10].
The clinical significance of survivin expression in pancre-
atic cancer is not well understood. Previous studies
reported that survivin was expressed at an incidence of
77%–88% [11,13]. In our study, survivin was expressed in
93.9%, and was highly expressed in most cases (59.2%).
In pathological parameters, neural invasion was more
common in survivin positive group. Neural invasion is a
specific metastatic route in pancreatic cancer and
perineural invasion is known to be a prognostic marker
for the recurrence of pancreatic cancer after surgery [14].
However, venous invasion was more common in survivin
negative group. Venous invasion in pancreatic cancer can
be a risk factor for liver metastasis [15]. We did not
explain this discrepancy, but we suggested that venous
invasion may be an independent prognostic factor irrele-
vant to survivin expression. Recent study reported that
survivin expression has different clinical significance
according to expression pattern [16]. Although we did not
distinguish the expression pattern, it may be another
explanation for this discrepancy. It is important to predict
recurrence or metastatic pattern after curative surgery
because of determining adequate adjuvant treatment
modality in pancreatic cancer, so further study may be
warranted to investigate the association between survivin
and pathological parameters.
We did not find any other association between survivin
expression and clinical course due to the limitation of
patients enrolled in this study. Most patients in our study
were at an early stage, making it difficult to compare sur-
vivin expression according to various stage. Secondly, the
vast majority of pancreatic cancer tissue in the present
study expressed survivin, meaning survivin-negative
Overall survival Figure 3
Overall survival. No significant difference in overall sur-
vival according to intensity of survivin expression.
Table 5: Stage and survivin, p53, bax expression
Stage I Stage II Stage III Stage IV p value
Survivin 0 0 2 0 1 0.386
13 7 5 2
25 1 7 5 2
p53 0 5 18 7 3 0.207
11 4 3 1
22 4 0 1
Bax 0 4 5 2 0 0.414
12 6 1 2
22 1 5 7 3BMC Cancer 2005, 5:127 http://www.biomedcentral.com/1471-2407/5/127
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group was very small. For the same reason, we could not
determine that survivin expression was a prognosis factor.
Recently, Kami et al reported that survivin expression may
be a prognostic factor in pancreatic cancer. In that study,
63.8% of patients showed survivin expression, resulting in
a good proportion of survivin-negative patients for com-
parison [17]. We also investigated whether survivin
expression was associated with poor clinical outcome,
including recurrence and survival, but no significant cor-
relation was observed. However, It is not determined that
survivin may not be associated with poor clinical outcome
because of limitation of our study. It may be that further
study involving great number of patients is required in
order to determine the clinical significance of survivin
expression in pancreatic cancer.
It is not certain whether survivin expression is a predictive
marker for anticancer therapy such as radiotherapy or
chemotherapy in pancreatic cancer. In a study using a
pancreatic cancer cell line, Asanuma et al reported that
survivin may be a radioresistant factor [12], and Kato et al
suggested that survivin expression may be a predictive
marker for chemotherapy as well as prognostic marker in
esophageal cancer in their previous study [9]. We exam-
ined the survivin expression in fourteen patients treated
with chemotherapy to evaluate the potential of survivin as
a predictive marker for chemotherapy. Although the
findings were statistically not significant, there was a sug-
gestion that non-responder group showed high survivin
expression. On the basis of this finding, we hypothesize
that survivin is a potential marker for predicting respon-
siveness to chemotherapy.
The p53 mutation is frequently seen in pancreatic cancer,
and its expression correlates with overall survival after
pancreatectomy [18]. Previous study found survivin and
p53 may play important roles in the transition from ade-
noma to carcinoma in situ in IPMT, and that survivin
expression was higher in p53-positive pancreatic cancers
[18,19]. In the present study, while 34.6% of tumors
expressed p53, there was no correlation between p53 and
survivin expression. Bcl-2 family proteins also play impor-
tant roles in regulation of apoptosis. Previous work
showed Bax expression was associated with a better prog-
nosis and was found to be a predictive marker for
adjuvant chemotherapy [20]. In the present study, while
84.6% of tumors expressed Bax, there was no correlation
between its expression and survivin expression or clinico-
pathological parameters. The present data did not indicate
that p53 or Bax protein correlated with survivin expres-
sion in pancreatic cancer. It is not certain why this
discrepancy exists, although all these proteins may block
apoptotic pathway. Whether p53 or Bax expression in
pancreatic cancer is related to prognosis is still under
debated. In addition, some authors suggest that survivin
may be independent prognostic marker not associated
with p53 or Bax expression [21,22]. Therefore, we hypoth-
esized that tumor cell may have other pathway to evade
apoptosis after Bax or p53-involved steps in pancreatic
cancer. It appears further large scale studies are required to
investigate any correlation between survivin and cell cycle
regulatory protein expression in pancreatic cancer.
Conclusion
In summary, survivin was expressed at high levels in the
vast majority of pancreatic cancer. While the data did not
indicate any correlation between survivin expression and
clinical outcome, they may be interpreted as suggesting
survivin may be a predictive marker in pancreatic cancer
for anticancer therapy in pancreatic cancer. We believe
further prospective studies are warranted to determine
whether survivin is a prognostic or predictive marker in
pancreatic cancer.
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Table 6: Pathological parameters and survivin expression
Lymphatic invasion 
(p = 0.094)
Venous invasion 
(p = 0.040)
Perineural invasion 
(p = 0.041)
Yes No Yes No Yes No
01 1 1 1 2 0
11 2 5 3 1 4 1 2 5
21 5 1 2 6 2 1 2 0 7
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